Every function can sign off on its own work, and the IND can still fail. Readiness depends on whether the connections between them hold.
Programs are planned in functional swim lanes, but risk lives at the interfaces, where one function’s output becomes another’s input. A tox NOAEL becomes a clinical dose ceiling. A CDMO contract becomes a global release path.
Here’s how the pieces connect.
The Functions
Development Strategy Sets the target product profile, population, route, dose concept, and global ambition that every other function builds against.
CMC Defines the drug product, specifications, and stability every other function assumes.
Nonclinical Establishes the safety margin and duration of coverage the clinical plan relies on.
Clinical Sets dose, population, and treatment duration, and must stay within what the evidence supports.
Regulatory Reconciles quality, nonclinical, and clinical evidence into one argument for FDA.
Quality Owns release, change control, and ongoing oversight of every partner.
Vendors (CDMOs & CROs) Their inspection history becomes your regulatory record the day the contract is signed.
Clinical Supply Delivers material at the volume, scale, and shelf life the protocol requires.
Global Development Determines which countries a program can enter without a second tech transfer.
Connections
CMC ↔ Nonclinical Same product? The material in the clinic must match what was tested in tox, or the difference must be bridged.
Nonclinical ↔ Clinical Same exposure? The safety margin must use the same route, regimen, and dose the protocol proposes.
CMC ↔ Clinical Same duration? Stability data and repeat-dose tox must cover the full treatment period.
Regulatory ↔ CMC FDA expects any differences between tox and clinical material to be disclosed.
Clinical ↔ Clinical Supply A larger, longer Phase 2 may need more material than the Phase 1 process can make.
Quality ↔ Vendors A quality agreement creates obligations, not oversight. Oversight takes risk-based audits and a named owner.
Vendors ↔ Global Development EU-inspected capacity and QP release provisions keep a European path open.
Global Development ↔ Clinical Supply US-only stability conditions and labeling can force costly rework later.
Key Timelines
- 12–18 months to scale up manufacturing for Phase 2 supply
- 6–12 months for long-lead nonclinical studies a Phase 2 protocol may trigger
- 30 days for FDA to review an IND — the least forgiving time to find a gap
How Syner-G Helps
Syner-G’s integrated CMC360 model treats the connections as the work. Our cross-functional teams test the full development argument at every gate, from strategy through Phase 2, so contradictions are caught internally, not under review.
Build an IND that holds together. Connect with our team.
synergbiopharma.com
